The documented U.S. regulatory footprint for this applicant centers on one premarket approval number, P010033, covering a cell-mediated immunity test for Mycobacterium tuberculosis in FDA product code NCD and device class 3. The supplied filing collection holds two linked records, both under the PMA pathway, with one approval and one 30-day notice among them. The original approval, dated 28 November 2001, names the applicant as Qiagen and describes approval for the Cellestis QuantiFERON-TB, indicated for use as an aid in the detection of infection with Mycobacterium tuberculosis. [1][2]
The approved product and its stated indication
The 2001 approval record lists the trade name QUANTTFERON-TB GOLD AND TB GOLD-IN-THE-TUBE, generic name Test, Immunity, Cell Mediated, Mycobacterium Tuberculosis, and an advisory committee of Microbiology. The approval statement limits the indication to use as an aid in detecting infection with Mycobacterium tuberculosis. The record carries an expedited review flag of Y and a Federal Register notice date of 13 May 2002. [2]
Current labeling describes QuantiFERON-TB Gold Plus as a whole-blood IFN-gamma test measuring responses to ESAT-6 and CFP-10 peptide antigens, for in vitro diagnostic use, offered in 2 x 96 (cat. no. 622130) and 20 x 96 (cat. no. 622832) configurations. The document is published by QIAGEN and lists the Germantown, Maryland address as the company contact on the instructions for use. [3]
Later supplement activity
A 30-day notice, P010033/S053, was received 14 September 2026 and decided 14 October 2026 with decision code OK30. Its supplement reason is a process change affecting manufacturer, sterilizer, packager or supplier, and the associated statement describes changes to the lyophilization process. The trade name on that record is QuantiFERON-TB Gold Plus Test, and the expedited review flag is N. [1]
Components and workflow as published
QIAGEN's product pages list QuantiFERON-TB Gold Plus Blood Collection Tubes, cat. no. 622536, supplied as 200 tubes (50 each of Nil, TB1, TB2 and Mitogen), and a Reference Lab Pack ELISA Kit, cat. no. 622832. The same pages state the product is for use as an aid in the detection of Mycobacterium tuberculosis infection, including disease. [4][7]
QIAGEN's testing-procedure page describes QFT-Plus as a blood test that helps identify people infected with M. tuberculosis and presents it as an alternative to the tuberculin skin test. It also describes an IGRA approach measuring T-cell response and gives handling steps, including return of samples to the testing lab at 2–8 degrees Celsius within 48 hours and incubation of QFT-Plus tubes at 37 degrees Celsius for 16–24 hours. [8]
How to read the filing counts
The supplied collection, as of 20 November 2026, contains two linked records, both on the PMA pathway, with decision counts of one OK30 and one APPR. The smaller record sample of two entries shows the same split. These figures describe the supplied filings only and are not measures of total company portfolio, sales or safety performance. [1][2]



